Global Fund Board announces integration of AMFm into core grant system

NewsGuard 100/100 Score

The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria on Thursday announced it will "integrate" the Affordable Medicines Facility-malaria (AMFm), implemented in 2010 as a pilot program to provide low-cost artemisinin-based combination therapies (ACTs) in poor and rural areas, "into its existing core system of providing grants to countries to purchase drugs, bed nets and other malaria-control measures," Nature News Blog reports (Butler, 11/15). "During a transition period in 2013, the lessons learned from the operations and resourcing of Phase 1 of the AMFm, such as manufacturer negotiations and the co-payment mechanism, will be integrated into core Global Fund processes," a Global Fund press release states.

With the program's integration, "there will no longer be a separate fund with external donor contributions to cover co-payments," and "[c]ountries will be responsible for allocating resources to implement a private sector strategy to expand access to malaria diagnosis and treatment in the private sector from their Global Fund malaria grants," according to the press release. Noting an independent evaluation of AMFm found the pilot program "was successful in increasing availability, decreasing retail prices, and increasing market share of quality-assured ACTs," the press release says the Board reached its decision "after extensive consultations with implementers, technical partners and donors about lessons learned" from the pilot phase (11/15).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Oxford University and Brazil partner to advance malaria vaccine development